AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP | Zendy

James B. Bussel | Zendy; David J. Kuter | Zendy; James N. George | Zendy; Robert McMillan | Zendy; Louis M. Aledort | Zendy; George T. Conklin | Zendy; Alan Lichtin | Zendy; Roger M. Lyons | Zendy; Jorge J. Nieva | Zendy; Jeffrey S. Wasser | Zendy; Israel Wiznitzer | Zendy; Reggie Kelly | Zendy; Chien-Feng Chen | Zendy; Janet L. Nichol | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP

Author(s) -

James B. Bussel,

David J. Kuter,

James N. George,

Robert McMillan,

Louis M. Aledort,

George T. Conklin,

Alan Lichtin,

Roger M. Lyons,

Jorge J. Nieva,

Jeffrey S. Wasser,

Israel Wiznitzer,

Reggie Kelly,

Chien-Feng Chen,

Janet L. Nichol

Publication year - 2006

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa054626

Subject(s) - medicine , thrombopoiesis , platelet , thrombocytopenic purpura , adverse effect , placebo , gastroenterology , surgery , megakaryocyte , pathology , stem cell , haematopoiesis , biology , genetics , alternative medicine

Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients with ITP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research